FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:332-333 August 4, 1994 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lenderking, W. R.

To the Editor: We disagree with the conclusion of Lenderking et al. (March 17 issue)¹ that the side effects of zidovudine make its use questionable in patients who have asymptomatic human immunodeficiency virus (HIV) infection. The most striking finding of the study was that there was no difference in symptomatic adverse events between the placebo group and the group treated with the recommended daily dose of 500 mg of zidovudine. The only difference was in "metabolic abnormalities" observed on laboratory analysis. It is difficult to understand how patients could regard a laboratory abnormality as affecting the quality of life as . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.